Raltegravir Potassium

拉替拉韦钾

Report date: 2022/05/17 11:54:19
NMEFirst In Class

Base Information

Drug NameRaltegravir Potassium
Drug Alias Name雷特格韦钾盐raltegravirum雷特格韦钾瑞特格韦钾劳特雷韦 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV integrase inhibitors
TargetsHIV integrase
Therapy Area/IndicationsCognitive DysfunctionDepressionHypertriglyceridemia +[12] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2007/10/12
Country/TerritoryCanadaBotswanaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of AlbertaMerck Sharp & Dohme CorpMerck Sharp & Dohme Bv +[5] 
Inactive CompaniesBristol Myers Squibb SrlcompanyRadboud University Medical CenterNational Institutes Of Health +[11] 
Active IndicationsCholangitis, SclerosingHIV Infections
Inactive IndicationsCognitive DysfunctionDepressionHypertriglyceridemia +[10] 

Other Information

ATC CodeJ05AJ01
Related LinksWikipediaDrugBankKEGG